Check Cap (MBAI) Stock Price
Check Cap Price
Check Cap stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Check Cap business model & stock analysis
Frequently asked questions about Check Cap
The business model of Check Cap Ltd is focused on developing and commercializing an ingestible capsule system for colorectal cancer screenings. This innovative technology, known as the C-Scan, utilizes ultra-low dose X-ray technology to generate 3D images of the colon. By providing a non-invasive and patient-friendly alternative to traditional colonoscopies, Check Cap aims to increase the accessibility and early detection of colorectal cancer. This approach holds great potential in improving global healthcare outcomes and reducing healthcare costs associated with colorectal cancer screenings. As a leader in medical imaging technology, Check Cap Ltd is committed to driving advancements in the field of gastroenterology and revolutionizing cancer diagnostics.
Check Cap Ltd is primarily active in the healthcare industry, specifically in the field of medical diagnostics.
The main competitors of Check Cap Ltd in the market include companies such as Exact Sciences Corporation, Cerner Corporation, and Medtronic plc.
Check Cap Ltd is a pioneering medical technology company founded in 2004. The company focuses on the development of innovative capsule-based solutions for the medical imaging industry. Check Cap Ltd specializes in developing the C-Scan® system, a patient-friendly device designed to detect colorectal polyps and other gastrointestinal abnormalities. With cutting-edge imaging technology and a commitment to improving patient care, Check Cap Ltd has become a leading player in the medical imaging industry. Known for its dedication to innovation and its focus on improving diagnostic procedures, Check Cap Ltd continues to make significant advancements in the field of gastrointestinal imaging.
Check Cap Ltd has achieved several significant milestones in its journey. Some notable achievements include the successful completion of clinical trials for its C-Scan system, which is a revolutionary ingestible capsule for colorectal cancer screening. The company has also obtained CE Mark approval for the C-Scan system, allowing it to be marketed and sold in Europe. In addition, Check Cap Ltd has entered into partnerships and collaborations with renowned healthcare institutions and industry leaders, further enhancing its position in the market. These milestones highlight Check Cap Ltd's commitment to developing innovative solutions for early detection and prevention of colorectal cancer.
Check Cap Ltd is primarily present in Israel, the United States, and Europe.
Check Cap Ltd is committed to upholding strong values and a clear corporate philosophy. As a company specializing in medical diagnostics, Check Cap prioritizes integrity, innovation, and excellence in its operations. By developing cutting-edge technologies, Check Cap aims to revolutionize the field of screening and early detection of colorectal cancer. The company's core philosophy revolves around patient care, providing non-invasive solutions for effective diagnosis. Check Cap Ltd strives to foster an environment of trust, transparency, and social responsibility, driving its commitment to improving healthcare outcomes and enhancing patients' lives.
6 analysts currently rate the Check Cap stock: 0 recommend buying, 3 holding and 3 selling. For 2026, analysts expect Check Cap to generate revenue of 4.76 M USD and earnings per share of -0.16 USD.
Converted at the current exchange rate, the Check Cap share trades at 2.45 EUR (2.75 USD).
The Check Cap share (MBAI) is listed on 3 stock exchanges, including: NASDAQ (CHEK), Frankfurt (7CC.F), München (7CC.MU).
Check Cap Ltd is a research-based medical technology company based in Israel. It develops products for the prevention, diagnosis, and monitoring of gastroenterological diseases, with its core product being the C-Scan®. The C-Scan® is a non-invasive, capsule-based technology that allows for the scanning of the entire digestive tract to detect potential tumors or other abnormalities early on. It offers an alternative to traditional colonoscopies and improves diagnostic accuracy. The C-Scan® is easy to use, painless, and requires no prior preparation or cleaning of the colon. Check Cap also conducts clinical studies to develop and test medications for gastroenterological diseases and works on new technologies for better visualization of the digestive tract. Its business model combines research and development, clinical studies, product development, and partnerships with other companies and institutions. With its innovative technology, Check Cap has the potential to change the way gastroenterological diseases are diagnosed, treated, and monitored.
The expected revenue of Check Cap is 4.76 M USD. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Check Cap is -145,800.00 USD. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Check Cap is currently -16.79. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Check Cap stock.
The price-to-sales ratio (P/S) of Check Cap is currently 0.51. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Check Cap stock.
The Eulerpool Quality Score for Check Cap is 2/10.
The ISIN of Check Cap is IL0011336851. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Check Cap is A14QUF. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Check Cap is MBAI. The ticker symbol is used to trade Check Cap shares on the stock exchange.
Check Cap stock
Check Cap Peer Group
Check Cap Ticker
Check Cap FIGI
All fundamentals and in-depth analysis of Check Cap
Our stock analysis for Check Cap stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Check Cap. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.